uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
New Hiring activity — 3 fresh signals just appeared.
The order this company entered each market — oldest to newest
Medical Director, UK
Vice President, Advertising and Promotion, Regulatory Affairs
Sign up to see the full signal feed
How UniQure's international expansion compares to its competitors
UniQureYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 UniQureYou | 2 | 0 | +100% | 3 | 31 |
Scaling fast — 8 roles opened in the last 90 days, up 67% vs the prior period. Education-led and concentrated in Netherlands.
United Kingdom · today
Medical Director, UK
Amsterdam, North Holland, Netherlands · 3d ago
Scientist Clinical Bioanalytics
Amsterdam, North Holland, Netherlands · 4d ago
Senior Director, Safety Operations
24 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
No media coverage in this window.
uniQure N.V. provides regulatory update on AMT-130, a gene therapy for Huntington's Disease. The company is advancing transformative therapies for patients with severe genetic diseases.
uniQure's experimental gene therapy shows potential to slow Huntington's disease progression by 75% over three years in a small trial.
uniQure's stock price surged 196% following positive results from their Huntington's disease drug trial, marking a significant breakthrough in treatment.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about UniQure's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
